
News|Articles|August 16, 2023
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
Author(s)Sydney Jennings
A daily dose of clinical news on Patient Care you may have missed.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on a study published in JAMA that examined the associations between intake of sugar-sweetened beverages, artificially sweetened beverages, and incidence of liver cancer and chronic liver disease mortality among postmenopausal women.
The study
A prospective analysis of data on beverage consumption among 98 786 postmenopausal women aged 50 to 79 years enrolled in the Women’s Health Initiative from 1993 to 1998. Participants were followed up to March 1, 2020.
Data from food frequency questionnaires administered at baseline provided the measure of sugar sweetened beverage intake over the study period that was defined as the sum of regular soft drinks and fruit drinks, excluding fruit juice. Investigators measured total intake of artificially sweetened beverages at the 3-year follow-up.
Researchers defined the study’s 2 primary outcomes as incident liver cancer and mortality due to chronic liver diseases including NAFLD, liver fibrosis, cirrhosis, alcoholic liver diseases and chronic hepatitis.
The findings
Results showed that the incidence of liver cancer was nearly 2-fold higher among those who consumed ≥1 daily serving of sugar sweetened beverages compared with those who consumed ≤3 servings monthly. Chronic liver disease-related mortality among the regular daily consumers of sugary drinks was more than 1.5 times higher than among the low monthly consumers.
Authors' commentary
"In postmenopausal women, compared with consuming 3 or fewer servings of sugar-sweetened beverages per month, people who consumed 1 or more sugar-sweetened beverages per day had higher rates of liver cancer and higher rates of death due to chronic liver disease. Future studies should confirm these findings and identify the biological pathways of these associations."
Click here for more details.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial
2
FDA Clears First At-Home Brain-Stimulation Device for Major Depression
3
Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis
4
ADA Publishes 2026 Standards of Care With Updates to Sections on Technology, Obesity, Cardiometabolic Disease Management
5





















































































































































































































































































